Perfect Holding completes Reverse Takeover Transaction with Kinarus
Perfect Holding announced the completion of the reverse takeover transaction (RTO) with Kinarus, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of viral, respiratory, and ophthalmic disease.
Perfect Holding acquired Kinarus by way of a share exchange. Kinarus shareholders representing 95.3% of its share capital have tendered their shares in exchange for newly issued shares of Perfect Holding, and such new shares have been admitted for listing and trading on the SIX Swiss Exchange as from 3 June 2022. In the coming days, Perfect Holding will complete the RTO process with a change of its name to Kinarus Therapeutics Holding and a move of its domicile to Basel, Switzerland. The ticker symbol will also be changed from PRFN to KNRS as of 9 June 2022.
Schellenberg Wittmer advised Kinarus in this transaction. The team consisted of partners Oliver Triebold (pictured), Marcel Jakob, Pascal Hubli, associate Nicolas Kurz, Laura Roth, Irisi Arifi (all corporate/m&a). In the same way Olivier Favre, Fabio Elsener, Dominic Wälchli, Daniel Reinger (all banking & finance), Michael Nordin, Roland Wild (all tax), Lorenza Ferrari Hofer, Dimitry Bölsterli (IP/life sciences) were also involved.
Bär & Karrer acted as legal counsel to Perfect Holding and Raiffeisen Switzerland as listing agent. Ventac Partners, corporate development, was also involved on this transaction.
